Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinically significant drug interaction between basiliximab and tacrolimus in renal transplant recipients.

× No keyword cloud information.

16 in total

Review 1. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.

Authors: Miroslav Dostalek; Iain Gardner; Brian M Gurbaxani; Rachel H Rose; Manoranjenni Chetty
Journal: Clin Pharmacokinet Date: 2013-02 Impact factor: 6.447

Review 2. CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications.

Authors: Jang-Ik Lee; Lei Zhang; Angela Y Men; Leslie A Kenna; Shiew-Mei Huang
Journal: Clin Pharmacokinet Date: 2010-05 Impact factor: 6.447

Review 3. Update on Therapeutic Protein-Drug Interaction: Information in Labeling.

Authors: Xing Jing; Ping Ji; Sarah J Schrieber; Elimika P Fletcher; Chandrahas Sahajwalla
Journal: Clin Pharmacokinet Date: 2020-01 Impact factor: 6.447

4. Significant increase in plasma 4β-hydroxycholesterol concentration in patients after kidney transplantation.

Authors: Yosuke Suzuki; Hiroki Itoh; Fuminori Sato; Kanako Kawasaki; Yukie Sato; Takashi Fujioka; Yuhki Sato; Keiko Ohno; Hiromitsu Mimata; Satoshi Kishino
Journal: J Lipid Res Date: 2013-07-04 Impact factor: 5.922

5. Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis.

Authors: Sauzanne Khalilieh; Azher Hussain; Diana Montgomery; Vanessa Levine; Peter M Shaw; Inga Bodrug; Lally Mekokishvili; Candice Bailey-Smith; Xiaoli S Glasgow; Amy Cheng; Monika Martinho; Marian Iwamoto
Journal: Br J Clin Pharmacol Date: 2018-07-31 Impact factor: 4.335

Review 6. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.

Authors: Agnieszka Swiatecka-Urban
Journal: Paediatr Drugs Date: 2003 Impact factor: 3.022

Review 7. Basiliximab: a review of its use as induction therapy in renal transplantation.

Authors: Therese M Chapman; Gillian M Keating
Journal: Drugs Date: 2003 Impact factor: 9.546

8. Therapeutic protein-drug interaction assessment for daclizumab high-yield process in patients with multiple sclerosis using a cocktail approach.

Authors: Jonathan Q Tran; Ahmed A Othman; Paul Wolstencroft; Jacob Elkins
Journal: Br J Clin Pharmacol Date: 2016-05-04 Impact factor: 4.335

9. Anti-interleukin-2 receptor antibodies-basiliximab and daclizumab-for the prevention of acute rejection in renal transplantation.

Authors: Junichiro Sageshima; Gaetano Ciancio; Linda Chen; George W Burke
Journal: Biologics Date: 2009-07-13

10. The role of basiliximab in the evolving renal transplantation immunosuppression protocol.

Authors: Paola Salis; Chiara Caccamo; Roberto Verzaro; Salvatore Gruttadauria; Mary Artero
Journal: Biologics Date: 2008-06